(IN BRIEF) Novartis has received FDA traditional approval for Fabhalta® (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression. Fabhalta is a first-in-class complement inhibitor targeting the alternative complement pathway. The approval … Read the full press release →
Posted in Business, Healthcare, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged accelerated approval, alternative complement pathway, APPLAUSE-IgAN, atrasentan, autoimmune kidney disease, Bonnie Schneider, Chronic kidney disease, complement inhibitor, Dana Rizk, dialysis, EGFR, encapsulated bacteria, Fabhalta, Fabhalta Approval Expands Targeted Treatment Options for Patients With Primary IgAN, Fabhalta Becomes First Complement Inhibitor Approved to Significantly Slow Kidney Function Decline in Primary IgAN, Factor B inhibitor, FDA, glomerular inflammation, IgA nephropathy, IgA Nephropathy Foundation, IgAN, iptacopan, kidney failure, kidney function decline, kidney transplantation, nephrology, Novartis, Novartis Highlights Kidney Function Preservation Data Behind Fabhalta FDA Approval, primary IgAN, Priority Review, proteinuria, rare kidney conditions, REMS programme, traditional approval, U.S. Food and Drug Administration, University of Alabama at Birmingham, Vanrafia, Victor Bultó, zigakibart
(IN BRIEF) Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% discount off list price for cash-paying patients. Cosentyx, a biologic approved for multiple immune-mediated … Read the full press release →
Posted in Healthcare, Marketing, Pharma & Biotech, Switzerland
Tagged biologics, Cosentyx, direct-to-employer model, direct-to-patient platform, discount medicines, drug affordability, DTP, hidradenitis suppurativa, immune-mediated inflammatory diseases, New Direct-to-Patient Platform from Novartis Aims to Reduce Barriers and Improve Affordability, Novartis, Novartis Launches Direct-to-Patient Platform in US with Discounted Access to Cosentyx, Novartis to Provide Patients Direct Access to Lower-Priced Cosentyx Starting November 2025, NPAF, patient access, patient assistance, psoriasis, psoriatic arthritis, secukinumab, specialty medicines, US healthcare, Victor Bultó
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
